Prediabetic state
Drug research and approvals for prediabetic state: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 162 studies of prediabetic state are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 162
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Fulvic Acid Supplementation and Metabolic SyndromeNCT07927283 · Not applicable · Arizona State University · starts Nov 6, 2026
- LIfestyle MEtabotype Study B (LIME-B)NCT07888257 · Not applicable · German Institute of Human Nutrition · starts Oct 26, 2026
- LIfestyle MEtabotype Study ANCT07868601 · Not reported · German Institute of Human Nutrition · starts Oct 10, 2026
- RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGMNCT07861191 · Not reported · National University Health System, Singapore · starts Jul 27, 2026
- Effects of Hourly Stair-Climbing Exercise Snacks on Metabolic and Vascular Health in Adults With PrediabetesNCT07847684 · Not applicable · St. Louis University · starts Oct 1, 2026
- Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in AgeingNCT07817290 · Not applicable · Azienda Ospedaliero Universitaria Maggiore della Carita · starts Jun 24, 2025
- Georgia CEAL RESTORES Family Diabetes StudyNCT07808723 · Not applicable · Morehouse School of Medicine · starts Aug 29, 2026
- Cardiorespiratory Fitness, Handgrip Strength, and Cardiometabolic Health in Obese Children With or Without Autism…NCT07804680 · Not reported · University of Virginia · starts Aug 5, 2026
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or…NCT07794579 · Phase 3 · Eli Lilly and Company · starts Aug 26, 2026
Phase 3 7
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- LiraglutideGlucagon-like peptide 1 receptor agonist
- Insulin glargineInsulin receptor agonist
- VildagliptinDipeptidyl peptidase IV inhibitor
- RimonabantCannabinoid CB1 receptor antagonist
- Alcohol
- Magnesium oxide
Phase 2 12
- ExenatideGlucagon-like peptide 1 receptor agonist
- NeomycinBacterial 70S ribosome inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- VancomycinPeptidoglycan inhibitor
- Berberine
- SitagliptinDipeptidyl peptidase IV inhibitor
- CholecalciferolVitamin D receptor agonist
- MirabegronBeta-3 adrenergic receptor agonist
- SimvastatinHMG-CoA reductase inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- MelatoninMelatonin receptor agonist
- Bifidobacterium spp.Probiotic
Phase 1 or earlier 4
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- CalcitriolVitamin D receptor agonist
- LysineRadioprotective agent
- Maltodextrin
How its trials ended
874 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 149 whose ending is known, 51% met their primary endpoint, 14% missed it and 35% stopped early.
- Completed, result not reported39345%
- Ongoing21324%
- Status unknown11914%
- Met its primary endpoint769%
- Stopped: other or unclear344%
- Missed its primary endpoint212%
- Stopped: funding81%
- Stopped: enrollment or feasibility51%
- Stopped: sponsor or business decision3<1%
- Stopped: lack of efficacy2<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA